Immunogenicity of COVID‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy
YJ Lim, V Ward, A Brown, E Phillips… - British Journal of …, 2024 - Wiley Online Library
Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with
follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016 …
follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016 …
[HTML][HTML] Back to the Future: Immune Protection or Enhancement of Future Coronaviruses
M Bartels, E Sala Solé, LM Sauerschnig, GT Rijkers - Microorganisms, 2024 - mdpi.com
Before the emergence of SARS-CoV-1, MERS-CoV, and most recently, SARS-CoV-2, four
other coronaviruses (the alpha coronaviruses NL63 and 229E and the beta coronaviruses …
other coronaviruses (the alpha coronaviruses NL63 and 229E and the beta coronaviruses …
[HTML][HTML] IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
H Xie, J Zhang, R Luo, Y Qi, Y Lin, C Han, X Li… - BMC immunology, 2024 - Springer
Background The ability of generating effective humoral immune responses to SARS-CoV-2
infection has not been clarified in lymphoma patients. The study aimed to investigate the …
infection has not been clarified in lymphoma patients. The study aimed to investigate the …
A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment
L Wu, X Qian, W Hu, S Wang, J Yan - 2024 - preprints.org
With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted
much attention as a potential therapeutic strategy. The potential role of the mannose …
much attention as a potential therapeutic strategy. The potential role of the mannose …